$3.35
0.19[6.01%]
At close: Apr 19
$3.35
0[0.00%]
After Hours: 8:57AM EDT
Acumen Pharmaceuticals
(NASDAQ:ABOS)Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Analyst Ratings, Price Targets, Predictions
Acumen Pharmaceuticals Inc has a consensus price target of $17.38, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Deutsche Bank, and Credit Suisse on March 27, 2024, December 12, 2023, and August 9, 2023. With an average price target of $12 between HC Wainwright & Co., Deutsche Bank, and Credit Suisse, there's an implied 258.21% upside for Acumen Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Deutsche Bank
Credit Suisse
B of A Securities
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Acumen Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | HC Wainwright & Co. | Andrew Fein | $15 → $15 | Maintains | Buy | Get Alert |
| 12/12/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 138.81% | Deutsche Bank | Neena Bitritto-Garg | → $8 | Initiates | → Buy | Get Alert |
| 08/09/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 288.06% | Credit Suisse | Judah Frommer | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/20/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 317.91% | B of A Securities | Geoff Meacham | → $14 | Reinstates | → Buy | Get Alert |
| 07/17/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 288.06% | Cantor Fitzgerald | Pete Stavropoulos | → $13 | Reiterates | Overweight → Overweight | Get Alert |
| 07/17/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/18/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 288.06% | Cantor Fitzgerald | Pete Stavropoulos | → $13 | Initiates | → Overweight | Get Alert |
| 03/28/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 288.06% | Credit Suisse | Judah Frommer | $16 → $13 | Maintains | Outperform | Get Alert |
| 03/28/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | → Buy | Get Alert |
| 02/02/2023 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | → Buy | Get Alert |
| 11/15/2022 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 377.61% | Credit Suisse | Judah Frommer | $17 → $16 | Maintains | Outperform | Get Alert |
| 10/05/2022 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 556.72% | BTIG | Thomas Shrader | $15 → $22 | Maintains | Buy | Get Alert |
| 07/15/2022 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | BTIG | Thomas Shrader | → $15 | Initiates | → Buy | Get Alert |
| 06/30/2022 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 347.76% | HC Wainwright & Co. | Andrew Fein | → $15 | Initiates | → Buy | Get Alert |
| 03/29/2022 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 407.46% | Credit Suisse | Judah Frommer | $26 → $17 | Maintains | Outperform | Get Alert |
| 01/21/2022 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 317.91% | B of A Securities | Geoff Meacham | $16 → $14 | Upgrade | Neutral → Buy | Get Alert |
| 07/26/2021 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 705.97% | UBS | Colin Bristow | — | Initiates | → Buy | Get Alert |
| 07/26/2021 | ABOS | Buy Now | Acumen Pharmaceuticals | $3.35 | 497.01% | B of A Securities | Geoff Meacham | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Acumen Pharmaceuticals (ABOS)?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by HC Wainwright & Co. on March 27, 2024. The analyst firm set a price target for $15.00 expecting ABOS to rise to within 12 months (a possible 347.76% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by HC Wainwright & Co., and Acumen Pharmaceuticals maintained their buy rating.
When was the last upgrade for Acumen Pharmaceuticals (ABOS)?
The last upgrade for Acumen Pharmaceuticals Inc happened on January 21, 2022 when B of A Securities raised their price target to $14. B of A Securities previously had a neutral for Acumen Pharmaceuticals Inc.
When was the last downgrade for Acumen Pharmaceuticals (ABOS)?
There is no last downgrade for Acumen Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a maintained with a price target of $15.00 to $15.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $3.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.